Study Summary
This trial tests a new drug to treat relapsed/refractory AML/MDS, a type of blood cancer.
- Relapsed/Refractory Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Relapsed or Refractory Acute Myeloid Leukemia
Treatment Effectiveness
Study Objectives
5 Primary · 1 Secondary · Reporting Duration: 28 Days
Trial Safety
Trial Design
4 Treatment Groups
Part C - Multiple ascending dose (MAD) design of SC administered CLN-049
1 of 4
Part A - Single ascending dose (SAD) design of IV administered CLN-049
1 of 4
Part B - Multiple ascending dose (MAD) design of IV administered CLN-049
1 of 4
Single Ascending Dose (SAD)
1 of 4
Experimental Treatment
60 Total Participants · 4 Treatment Groups
Primary Treatment: CLN-049 · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What is the upper limit for participants in this clinical experiment?
"This medical trial demands the enrollment of 60 individuals who meet its entry requirements. Potential participants can be found at either Emory University Hospital in Atlanta, Georgia or UCLA in Los Angeles, California." - Anonymous Online Contributor
How many sites in Canada are conducting this clinical research?
"The trial is currently inviting participants to join from 7 different medical sites, located in several cities including Atlanta, Los Angeles and Tampa. It may be advantageous for you if the closest centre to your area of residence participates so as to reduce travel demands." - Anonymous Online Contributor
What perils could individuals face when exposed to CLN-049?
"CLN-049's safety profile has been evaluated as a 1 on the Power scale due to it being in its initial clinical testing stage, where data supporting efficacy and safety is still limited." - Anonymous Online Contributor
Are there still vacancies available to participate in this experiment?
"Affirmative. The information found on clinicaltrials.gov confirms that the trial is recruiting participants, with an original posting date of November 18th 2021 and a recent update on December 6th 2022. This study needs to acquire 60 individuals from 7 distinct locations." - Anonymous Online Contributor